| Title |
Recent advances in the treatment of premature ejaculation
|
|---|---|
| Published in |
Drug Design, Development and Therapy, January 2010
|
| DOI | 10.2147/dddt.s6077 |
| Pubmed ID | |
| Authors |
Kate D Linton, Kevan R Wylie |
| Abstract |
Premature ejaculation (PE) is the most common sexual problem affecting men. It can affect men at all ages and has a serious impact on the quality of life for men and their partners. Currently there are no pharmaceutical agents approved for use in the UK, and so all drugs used for this condition are off label. Behavioral therapy has been used to treat PE, but the results are not durable once therapy has been concluded. Several topical therapies have been used including severance-secret (SS) cream, lignocaine spray, lidocaine-prilocaine cream and lidocaine-prilocaine spray (TEMPE). There has been recent interest in the selective serotonin reuptake inhibitors (SSRIs) for the treatment of PE, due to the fact that one of their common side effects is delayed ejaculation. Currently used SSRIs have several non-sexual side effects and long half lives, therefore there has been interest in developing a short acting, efficacious SSRI that can be used on-demand for PE. Dapoxetine has been recently evaluated for the treatment of PE by several groups, and results so far appear promising. |
Mendeley readers
The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | 3% |
| Unknown | 39 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 10 | 25% |
| Student > Doctoral Student | 5 | 13% |
| Researcher | 4 | 10% |
| Student > Bachelor | 4 | 10% |
| Student > Postgraduate | 4 | 10% |
| Other | 10 | 25% |
| Unknown | 3 | 8% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 45% |
| Agricultural and Biological Sciences | 5 | 13% |
| Nursing and Health Professions | 3 | 8% |
| Psychology | 3 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Other | 4 | 10% |
| Unknown | 5 | 13% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 May 2011.
All research outputs
#8,713,411
of 25,806,080 outputs
Outputs from Drug Design, Development and Therapy
#662
of 2,283 outputs
Outputs of similar age
#51,922
of 174,995 outputs
Outputs of similar age from Drug Design, Development and Therapy
#3
of 3 outputs
Altmetric has tracked 25,806,080 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,283 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 174,995 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.